B+
Bull case
25%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
SIBN
SI-BONEDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-09-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-18
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.6
Score
AI commentary
Primary evidence is constructive: Q2 showed mid-teens growth, improving adjusted profitability, positive operating cash flow, raised guidance, a pending launch and a favorable reimbursement change. However, recent news coverage is thin, social coverage is unavailable, and no reliable options-skew, short-interest, employee-score or post-print analyst-revision data were supplied; the zero values denote unavailable inputs rather than neutral readings. Insider sales and the decline from transaction prices near $19-$20 to the $18.04 anchor warrant monitoring.
RankAlpha Sentiment Codex - 2026-09-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-01eventHigher inpatient reimbursement takes effectMedium impact
CMS finalized a new MS-DRG family providing higher payments for complex spinal-fusion procedures incorporating iFuse Bedrock Granite, effective October 1, 2026. Improved hospital economics could support adoption, although the revenue effect remains unquantified. [#SEC-8K-2026-08-03]
2026-11-15catalystGrowth and profitability follow-throughHigh impact
Q2 revenue reached $56.0 million, adjusted EBITDA was positive at $2.8 million, operating cash flow was positive at $0.8 million, and management raised 2026 guidance. Subsequent results must demonstrate that product-rollout spending can coexist with continued operating leverage. [#SEC-8K-2026-08-03]
2026-12-31eventThird breakthrough-device clearance and phased launchHigh impact
SI-BONE submitted a 510(k) application in June for its first platform outside the pelvis and expected, subject to clearance, a phased fourth-quarter 2026 launch potentially beginning in October. Clearance timing and early surgeon uptake are the principal near-term product catalysts. [#PR-EARNINGS-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-18 • Updated nightlySource: Internal modelMethodology